Official Website: Techcyte
source confidence: Medium status: Useful updated 2026-06-18
Summary
Techcyte's official website describes Fusion, a unified anatomic and clinical digital-pathology platform with AI-assisted workflows for surgical pathology, cytology, microbiology, hematology, veterinary diagnostics, and related markets. The company is headquartered in Orem, Utah.
Useful Claims
- Fusion is positioned as the first unified anatomic and clinical pathology AI platform, spanning tissue and liquid-based workflows.
- Product suite includes Fusion AP, Fusion Frozen Section Suite, Techcyte SureView Cervical Cytology System, and Fusion suites for parasitology, bacteriology, hematology, and organ donation.
- Fusion AP is described as CE-IVDR certified; U.S. regulatory status varies by product (site notes research-use-only positioning for some U.S. offerings).
- Compliance framing references FDA, CE, HIPAA, ISO, GDPR, and SOC2.
- Orem, Utah addresses listed: 1106 N 1200 W and 105 S State Street.
- Public collaborations referenced include BD, Mayo Clinic Platform, and Zoetis-related veterinary work.
Verbatim
"Discover the world's first digital pathology platform that unites clinical and anatomic pathology into one seamless solution, revolutionizing workflows and improving the lives of pathologists." — Home page, Fusion heading
"The only unified anatomic & clinical pathology AI platform" — Home page, "Techcyte Fusion"
"Fusion AP is now CE-IVDR certified" — Home page, announcement banner
"Compliance: FDA, CE, HIPAA, ISO, GDPR, SOC2" — Home page, Fusion feature list
"Headquarters: 1106 N 1200 W Orem, UT 84057 Mailing Address: 105 S State Street, #401 Orem, UT 84058" — Home page, footer
Reliability Notes
Official company source — reliable for product names, positioning, and Orem location. Regulatory status, customer counts, revenue, and clinical-performance claims require corroboration from FDA databases, peer-reviewed publications, and SEC or press materials. April 2026 financing and Mayo Safe Harbor dataset details appear in venture-page secondary coverage and should be verified against primary announcements.